Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC
- PMID: 20029441
- DOI: 10.1038/nrclinonc.2009.173
Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC
Abstract
Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-alpha as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer.
Comment on
-
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1. J Clin Oncol. 2009. PMID: 19487381 Free PMC article. Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources
